AstraZeneca’s Alexion concludes Caelum acquisition for $500m

AstraZeneca’s Alexion concludes Caelum acquisition for $500m

Submitted by admin on October 7, 2021 - 11:22am
Source: 
Pharmaceutical Business Review
News Tags: 
AstraZeneca
Alexion
Caelum Biosciences
M&A
Headline: 
AstraZeneca’s Alexion concludes Caelum acquisition for $500m
snippet: 


AstraZeneca subsidiary Alexion has concluded the takeover of all the outstanding shares of Caelum Biosciences in a deal worth up to $500m.

Do Not Allow Advertisers to Use My Personal information